SCHEMBL701931

SCHEMBL701931

CCOC(=O)c1cncc(B2OC(C)(C)C(C)(C)O2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.55
CYP2C9 P11712 1/20 0.55
UCHL1 P09936 1/20 0.45
ALDH1A1 P00352 2/20 0.41
MAPT P10636 1/20 0.41
CA12 O43570 3/20 0.40
CA1 P00915 3/20 0.40
CA2 P00918 3/20 0.40
CA7 P43166 3/20 0.40
CA9 Q16790 3/20 0.40
CA14 Q9ULX7 3/20 0.40
SMN1; SMN2 Q16637 1/20 0.39
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
ATM Q13315 1/20 0.38
KDM4E B2RXH2 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP3A4 P08684 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
ESR1 P03372 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14880510 0.96 CYP2C19 (0.51) CYP2C19CYP2C9UCHL1ALDH1A1MAPT
SCHEMBL1052988 0.85 ATM (0.51) CYP2C19CYP2C9UCHL1ALDH1A1CA12
SCHEMBL30121332 0.85 ATM (0.51) CYP2C19CYP2C9UCHL1ALDH1A1CA12
SCHEMBL14746472 0.84 CA12 (0.49) CYP2C19CYP2C9UCHL1ALDH1A1MAPT
SCHEMBL1601462 0.83 CYP2C19 (0.48) CYP2C19CYP2C9UCHL1ALDH1A1MAPT
SCHEMBL25408178 0.81 USP30 (0.40) CYP2C19CYP2C9GSK3AGSK3BATM
SCHEMBL13348317 0.81 CYP2C19 (0.55) CYP2C19CYP2C9ALDH1A1MAPTCA12
SCHEMBL16872278 0.80 HCAR2 (0.47) CYP2C19CYP2C9ALDH1A1GSK3AGSK3B
SCHEMBL1302760 0.80 MKNK1 (0.39) CA1CA2CA9GSK3AGSK3B
SCHEMBL16559890 0.80 CA12 (0.44) CYP2C19CYP2C9UCHL1CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 151 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118725377-A Preparation method of water-blocking polyvinyl alcohol-based coating fresh-keeping packaging material 安徽紫金新材料科技股份有限公司 2024-10-01 CN claimed
EP-4747247-A1 NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF Apogee Pharmaceuticals, Inc. (CA) 2026-05-27 EP disclosed
US-12552772-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD SPRINGWORKS THERAPEUTICS, INC. (US) 2026-02-17 US disclosed
US-12410137-B2 Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-09-09 US disclosed
US-20250129027-A1 FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2025-04-24 US disclosed
US-20250115574-A1 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD VIB VZW (BE) 2025-04-10 US disclosed
WO-2025015420-A1 NOVEL FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2025-01-23 WO disclosed
EP-4452253-A2 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD The Katholieke Universiteit Leuven (BE) 2024-10-30 EP disclosed
EP-3792256-B1 PYRIDINE COMPOUNDS AS PI3K-GAMMA INHIBITORS INCYTE CORP (US) 2024-10-23 EP disclosed
CN-118725377-A Preparation method of water-blocking polyvinyl alcohol-based coating fresh-keeping packaging material 安徽紫金新材料科技股份有限公司 2024-10-01 CN disclosed
EP-2102199-A1 ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS AstraZeneca AB (SE) 2009-09-23 EP disclosed
WO-2009106885-A1 HETEROCYCLIC UREA DERIVATIVES AND METHODS OF USE THEREOF-211 ASTRAZENECA AB (SE) 2009-09-03 WO disclosed
EP-2076509-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE Merck Frosst Canada Ltd. (CA) 2009-07-08 EP disclosed
US-7550470-B2 Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors MERCK & CO. INC. (US) 2009-06-23 US disclosed
US-7550470-B2 Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors MERCK & CO. INC. (US) 2009-06-23 US disclosed
WO-2009024825-A1 2-PYRAZINYLBENZIMIDAZOLE DERIVATIVES AS RECEPTOR TYROSINE KINASE INHIBITORS ASTRAZENECA AB (SE) 2009-02-26 WO disclosed
WO-2008068470-A1 ANTIBACTERIAL POLYCYCLIC UREA COMPOUNDS ASTRAZENECA AB (SE) 2008-06-12 WO disclosed
US-20080132546-A1 CHEMICAL COMPOUNDS ASTRAZENECA AB (SE) 2008-06-05 US disclosed
WO-2008046226-A1 AZACYCLOALKANE DERIVATIVES AS INHIBITORS OF STEAROYL-COENZYME A DELTA-9 DESATURASE MERCK FROSST CANADA LTD. (CA) 2008-04-24 WO disclosed
WO-2006130673-A1 3-BENZOIMIDAZOLYL-PYRAZOLOPYRIDINES USEFUL IN TREATING KINASE DISORDERS JANSSEN PHARMACEUTICA, N.V. (BE) 2006-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250129027-A1 FATTY ACID AMIDE HYDROLASE MODULATORS, COMPOSITIONS COMPRISING THE SAME AND USES THEREOF FAAH, FAAH2, MGLL CYP2C19 575/4885CYP2C9 425/4885UCHL1 559/4885
US-12552772-B2 2-pyrazole anilines and related analogs for inhibiting YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 CYP2C19 3870/4885CYP2C9 3168/4885UCHL1 4331/4885
US-12410137-B2 Fatty acid amide hydrolase modulators, compositions comprising the same and uses thereof FAAH, FAAH2, MGLL CYP2C19 575/4885CYP2C9 425/4885UCHL1 559/4885
US-20080132546-A1 CHEMICAL COMPOUNDS MRPL21, NISCH, ABCB11 CYP2C19 6/4885CYP2C9 11/4885UCHL1 3353/4885
US-20250115574-A1 2-PYRAZOLE ANILINES AND RELATED ANALOGS FOR INHIBITING YAP/TAZ-TEAD YAP1, TEAD3, TEAD2 CYP2C19 4810/4885CYP2C9 4644/4885UCHL1 4284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.